F S&P 500
5,544.50 +7.50 (+0.14%) F Dow Jones
39,530.00 +4.00 (+0.01%) F Nasdaq
20,016.25 +44.00 (+0.22%) E-mini Russell 2000 Index Futur
2,044.80 -0.10 (-0.00%) Petróleo
81.38 +0.55 (+0.68%) Oro
2,327.00 -3.80 (-0.16%)
Vincerx Pharma, Inc. (VINC)
Fuera de horario:
Vincerx Pharma, Inc.
260 Sheridan Avenue
Suite 400
Palo Alto, CA 94306
United States
650 800 6676
https://vincerx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 42
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Ahmed M. Hamdy M.D. | Co-Founder, Chairman & CEO | 657.54k | N/D | 1965 |
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, President, COO, Secretary & Director | 591.54k | N/D | 1970 |
| Mr. Alexander A. Seelenberger M.B.A. | Chief Financial Officer | 491.69k | N/D | 1979 |
| Mr. Tom C. Thomas J.D. | Founder, General Counsel & Chief Legal Officer | 444.14k | N/D | 1960 |
| Dr. John C. Byrd M.D. | Founder & Chairman of Scientific Advisory Board | N/D | N/D | N/D |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer | N/D | N/D | N/D |
| Ms. Gabriela Jairala | Sr Executive Director of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Ms. Karen Quarford | Vice President of Quality Operations & Compliance | N/D | N/D | N/D |
| Ms. Melissa Merrick SPHR | Senior Director of People & Culture and Head of Human Resource | N/D | N/D | N/D |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer | N/D | N/D | N/D |
Descripción
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Vincerx Pharma, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
